ClinicalTrials.gg
CompletedNCT00479401Updated Jul 17, 2014Results posted

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

A Phase 3 interventional study of Pramipexol Extended Release and Pramipexol Immediate Release in Early Parkinson Disease (Early PD), sponsored by Boehringer Ingelheim. Completed at 95 sites in 14 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-07-17.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
539
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
3rd of 26
539 · median 224
Started
2007
with 4 others
Phase 3
11 of 26
none open now
Registered
10th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 10th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III combined), safety, and tolerability of Pramipexole Extended Release (ER) (in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole.

In addition, the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo, for assay sensitivity

03

Conditions studied

  • Early Parkinson Disease (Early PD)

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient with idiopathic Parkinsons disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2. Parkinsons disease diagnosed within 5 years.
  3. Patients 30 years of age or older at the time of diagnosis.
  4. Modified Hoehn and Yahr stage of 1 to 3.
  5. Patients requiring additional therapy/ introduction of therapy (for de novo patients) to treat their parkinsonian symptoms at the time of enrollment (screening visit, V1) according to the investigators judgement.

Exclusion criteria

Exclusion Criteria:

  1. Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).
  2. Dementia, as defined by a score \< 24 at screening visit
  3. Any psychiatric disorder according to 4th (DSM-IV)
  4. History of psychosis
  5. (ECG) abnormalities at screening visit
  6. Clinically significant hypotension
  7. Malignant melanoma or history of previously treated malignant melanoma
  8. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study
  9. Pregnancy
  10. Sexually active female of not using a medically approved method of
  11. Serum levels of (AST) , Alanine Aminotransferase (ALT), alkaline phosphatases or > 2 (ULN)
  12. Patients with a \< 50 mL/min
  13. Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit, or L-Dopa within 8 weeks prior to baseline visit.
  14. Total cumulative duration of prior exposure to Levodopa of more than 3 months.
  15. Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit
  16. Any of the following drugs within 4 weeks prior to the baseline visit: methylphenidate, cinnarizine, amphetamines.
  17. Flunarizine within 3 months prior to baseline visit
  18. Known to Pramipexole or its
  19. Drug abuse (including alcohol), according to Investigators judgement, within 2 years prior to screening.
  20. Participation in other drug studies or use of other investigational drugs within one month or five times the half-life of the investigational drug
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
539 participants (actual)

Study arms

  • Experimental
    Pramipexole Extended Release (PPX ER)

    Drug: Pramipexol Extended Release

  • Experimental
    Pramipexole Immediate Release (PPX IR)

    Drug: Pramipexol Immediate Release

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score

    Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.

    Time frame: baseline and after 33 weeks treatment

Secondary outcomes

  1. Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale

    Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale

    Time frame: after 18 weeks of treatment compared to baseline

  2. Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale

    Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.

    Time frame: after 18 weeks of treatment compared to baseline

  3. UPDRS II+III Responder Rate (at Least 20% Improvement)

    Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.

    Time frame: after 33 weeks treatment

  4. UPDRS Part I Change From Baseline

    UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement

    Time frame: baseline and after 33 weeks treatment

  5. UPDRS Part II Total Score

    UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement

    Time frame: after 33 weeks treatment

  6. UPDRS Part III Total Score

    UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement

    Time frame: after 33 weeks treatment

  7. Beck's Depression Inventory Version I A

    The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).

    Time frame: after 33 weeks treatment

  8. Likert Scale for Pain Related to PD

    Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement

    Time frame: after 33 weeks treatment

  9. Parkinson's Disease Sleep Scale (PDSS)

    PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)

    Time frame: after 33 weeks treatment

  10. Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include: * mobility (e.g. fear of falling when walking): 10 items * activities of daily living (e.g. difficulty cutting food): 6 items * emotional well-being (e.g. feelings of isolation): 6 items * stigma (e.g. social embarrassment): 4 items * social support: 3 items * cognition: 4 items * communication: 3 items * bodily discomfort: 3 items. A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.

    Time frame: after 33 weeks treatment

  11. Change From Baseline in European Quality of Life Visual Analog Scale

    European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.

    Time frame: after 33 weeks treatment

  12. Patients Who Started to Use L-Dopa Rescue Medication

    L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population

    Time frame: from trial start on to any time before final assessment of the patient, up to 33 weeks

  13. Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)

    mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).

    Time frame: from trial start on to any time before final assessment of the patient, up to 33 weeks

  14. Possible Clinically Significant Abnormal Laboratory Parameters

    The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.

    Time frame: baseline and after 33 weeks of treatment

  15. Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events

    Time frame: baseline and after 33 weeks of treatment

07

Results

Posted Apr 15, 2010

Participant flow

Participant flow — Overall Study
MilestonePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Started223213103
Completed17417691
Not completed493712
Withdrew: Adverse event24204
Withdrew: Lack of efficacy224
Withdrew: Protocol violation211
Withdrew: Lost to follow-up111
Withdrew: Withdrawal by subject16102
Withdrew: Exclusion criteria, relocation430

Outcome measures

PrimaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score

Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.

Time frame:
baseline and after 33 weeks treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score-8.6 (-9.9 to -7.2)-8.8 (-10.2 to -7.4)-3.8 (-5.9 to -1.8)
Statistical analysis
  • Pramipexole Extended Release (PPX ER) vs Pramipexole Immediate Release (PPX IR) · ANCOVA · Mean difference (final values): -0.2 · 95% CI -2.2 to 1.7PPX ER non-inferior to PPX IR, if the lower limit of the confidence interval for the difference is higher than the non-inferiority margin of -3
SecondaryPercentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale

Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale

Time frame:
after 18 weeks of treatment compared to baseline
Reported as:
Number · Percentage of Participants
Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale
Percentage of ParticipantsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale374818
SecondaryPercentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale

Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.

Time frame:
after 18 weeks of treatment compared to baseline
Reported as:
Number · Percentage of Participants
Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale
Percentage of ParticipantsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale35.623.812
SecondaryUPDRS II+III Responder Rate (at Least 20% Improvement)

Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.

Time frame:
after 33 weeks treatment
Reported as:
Number · percentage of responders
UPDRS II+III Responder Rate (at Least 20% Improvement)
percentage of respondersPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
UPDRS II+III Responder Rate (at Least 20% Improvement)68.565.748.5
SecondaryUPDRS Part I Change From Baseline

UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement

Time frame:
baseline and after 33 weeks treatment
Reported as:
Median · units on a scale
UPDRS Part I Change From Baseline
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
UPDRS Part I Change From Baseline0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)
SecondaryUPDRS Part II Total Score

UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
UPDRS Part II Total Score
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
UPDRS Part II Total Score-2.2 (-2.6 to -1.7)-2.4 (-2.9 to -2.0)-0.9 (-1.5 to -0.3)
SecondaryUPDRS Part III Total Score

UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
UPDRS Part III Total Score
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
UPDRS Part III Total Score-6.4 (-7.4 to -5.4)-6.4 (-7.4 to -5.4)-2.8 (-4.2 to -1.4)
SecondaryBeck's Depression Inventory Version I A

The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
Beck's Depression Inventory Version I A
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Beck's Depression Inventory Version I A-2.0 (-2.7 to -1.3)-2.7 (-3.4 to -2.0)-2.1 (-3.1 to -1.2)
SecondaryLikert Scale for Pain Related to PD

Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
Likert Scale for Pain Related to PD
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Likert Scale for Pain Related to PD-0.2 (-0.4 to 0.1)-0.1 (-0.4 to 0.1)0.2 (-0.2 to 0.5)
SecondaryParkinson's Disease Sleep Scale (PDSS)

PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
Parkinson's Disease Sleep Scale (PDSS)
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Parkinson's Disease Sleep Scale (PDSS)2.3 (-0.4 to 5.0)5.6 (2.8 to 8.4)5.6 (1.8 to 9.4)
SecondaryChange From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include: * mobility (e.g. fear of falling when walking): 10 items * activities of daily living (e.g. difficulty cutting food): 6 items * emotional well-being (e.g. feelings of isolation): 6 items * stigma (e.g. social embarrassment): 4 items * social support: 3 items * cognition: 4 items * communication: 3 items * bodily discomfort: 3 items. A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score-4.1 (-6.1 to -2.0)-6.5 (-8.6 to -4.5)-2.1 (-4.9 to 0.8)
SecondaryChange From Baseline in European Quality of Life Visual Analog Scale

European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.

Time frame:
after 33 weeks treatment
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life Visual Analog Scale
units on a scalePramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Change From Baseline in European Quality of Life Visual Analog Scale4.0 (1.4 to 7.6)6.6 (3.9 to 9.2)3.2 (-0.4 to 6.9)
SecondaryPatients Who Started to Use L-Dopa Rescue Medication

L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population

Time frame:
from trial start on to any time before final assessment of the patient, up to 33 weeks
Reported as:
Number · patients
Patients Who Started to Use L-Dopa Rescue Medication
patientsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Patients Who Started to Use L-Dopa Rescue Medication15922
SecondaryNumber of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)

mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).

Time frame:
from trial start on to any time before final assessment of the patient, up to 33 weeks
Reported as:
Number · patients
Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)
patientsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)431
SecondaryPossible Clinically Significant Abnormal Laboratory Parameters

The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.

Time frame:
baseline and after 33 weeks of treatment
Reported as:
Number · participants
Possible Clinically Significant Abnormal Laboratory Parameters
participantsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Haematocrit - decrease4 ± 9.83 ± 10.11 ± 10.7
Haemoglobin - decrease1161
Red blood cell ct. - decrease100
White blood cell ct. - decrease100
Neut., poly (segs) - decrease200
Eosinophils - increase633
Neut., poly (segs), absol. - decrease100
Sodium - decrease550
Potassium - increase310
Chloride - decrease200
Alkaline phosphatase - increase010
GGT - increase310
Glucose - decrease300
Glucose - increase110
Cholesterol, total - increase001
Creatinine - increase001
Triglyceride - increase935
Uric acid - increase312
SecondaryClinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events
Time frame:
baseline and after 33 weeks of treatment
Reported as:
Number · participants
Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events
participantsPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Hypertension675
Orthostatic hypotension711
Hypotension061
Weight increased070
Weight decreased230
Blood pressure diastolic increased010

Adverse events

Collected over from trial start on to any time before final assessment of the patient, up to 33 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole Extended Release (PPX ER)—16/223 (7.2%)142/223 (63.7%)
Pramipexole Immediate Release (PPX IR)—11/213 (5.2%)133/213 (62.4%)
Placebo—4/103 (3.9%)44/103 (42.7%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
Vertigo positionalEar and labyrinth disorders0/2230/2131/103
CholecystitisHepatobiliary disorders0/2230/2131/103
CholelithiasisHepatobiliary disorders0/2231/2131/103
Radius fractureInjury, poisoning and procedural complications0/2230/2131/103
Back painMusculoskeletal and connective tissue disorders1/2231/2131/103
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2230/2130/103
Atrial fibrillationCardiac disorders0/2231/2130/103
Myocardial infarctionCardiac disorders0/2231/2130/103
PericarditisCardiac disorders0/2231/2130/103
DiarrhoeaGastrointestinal disorders0/2231/2130/103
Most frequent other events
Most frequent other events
EventPramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)Placebo
SomnolenceNervous system disorders81/22370/21315/103
NauseaGastrointestinal disorders48/22351/2139/103
ConstipationGastrointestinal disorders31/22325/2132/103
DizzinessNervous system disorders26/22325/2137/103
Oedema peripheralGeneral disorders12/22318/2134/103
NasopharyngitisInfections and infestations14/2239/2138/103
HeadacheNervous system disorders7/22315/2136/103
FatigueGeneral disorders14/22311/2134/103
Back painMusculoskeletal and connective tissue disorders11/22311/2136/103
Dry mouthGastrointestinal disorders12/2238/2131/103

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)PlaceboTotal
Mean61.3 ± 9.861.7 ± 9.662.0 ± 9.661.6 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole Extended Release (PPX ER)Pramipexole Immediate Release (PPX IR)PlaceboTotal
Female969252240
Male12712151299
08

Study locations

95 sites
  • 248.524.01018 Boehringer Ingelheim Investigational Site
    Gilbert, Arizona, United States
  • 248.524.01004 Boehringer Ingelheim Investigational Site
    Sun City, Arizona, United States
  • 248.524.01016 Boehringer Ingelheim Investigational Site
    La Jolla, California, United States
  • 248.524.01013 Boehringer Ingelheim Investigational Site
    Oxnard, California, United States
  • 248.524.01008 Boehringer Ingelheim Investigational Site
    Danbury, Connecticut, United States
  • 248.524.01010 Boehringer Ingelheim Investigational Site
    Boca Raton, Florida, United States
  • 248.524.01014 Boehringer Ingelheim Investigational Site
    Augusta, Georgia, United States
  • 248.524.01012 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.524.01001 Boehringer Ingelheim Investigational Site
    Kansas City, Kansas, United States
  • 248.524.01007 Boehringer Ingelheim Investigational Site
    Elkridge, Maryland, United States
  • 248.524.01015 Boehringer Ingelheim Investigational Site
    Southfield, Michigan, United States
  • 248.524.01017 Boehringer Ingelheim Investigational Site
    Hattiesburg, Mississippi, United States
  • 248.524.01005 Boehringer Ingelheim Investigational Site
    Commack, New York, United States
  • 248.524.01002 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 248.524.01003 Boehringer Ingelheim Investigational Site
    Midvale, Utah, United States
  • 248.524.01009 Boehringer Ingelheim Investigational Site
    Burlington, Vermont, United States
  • 248.524.54001 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 248.524.54002 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 248.524.54003 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 248.524.54007 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 248.524.54008 Instituto de Neurociencias de Buenos Aires
    Capital Federal, Argentina
  • 248.524.54009 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 248.524.54006 Boehringer Ingelheim Investigational Site
    Mar del Plata, Argentina
  • 248.524.54004 Boehringer Ingelheim Investigational Site
    Santa Fe, Argentina
  • 248.524.43001 Boehringer Ingelheim Investigational Site
    Innsbruck, Austria
  • 248.524.43004 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 248.524.42004 Boehringer Ingelheim Investigational Site
    Olomouc, Czech Republic
  • 248.524.42003 Boehringer Ingelheim Investigational Site
    Pardubice, Czech Republic
  • 248.524.42001 Boehringer Ingelheim Investigational Site
    Praha, Czech Republic
  • 248.524.42002 Boehringer Ingelheim Investigational Site
    Rychnov nad Kneznou, Czech Republic
  • 248.524.35803 Boehringer Ingelheim Investigational Site
    Hyvinkää, Finland
  • 248.524.35801 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 248.524.35802 Boehringer Ingelheim Investigational Site
    Tampere, Finland
  • 248.524.49002 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.524.49003 Boehringer Ingelheim Investigational Site
    Bochum, Germany
  • 248.524.49011 Boehringer Ingelheim Investigational Site
    Bochum, Germany
  • 248.524.49008 Boehringer Ingelheim Investigational Site
    Bremerhaven, Germany
  • 248.524.49006 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 248.524.49007 Boehringer Ingelheim Investigational Site
    Göttingen, Germany
  • 248.524.49001 Boehringer Ingelheim Investigational Site
    Kassel, Germany
  • 248.524.49004 Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • 248.524.49005 Boehringer Ingelheim Investigational Site
    Marburg, Germany
  • 248.524.36007 Boehringer Ingelheim Investigational Site
    Eger, Hungary
  • 248.524.36005 Boehringer Ingelheim Investigational Site
    Györ, Hungary
  • 248.524.36008 Boehringer Ingelheim Investigational Site
    Miskolc, Hungary
  • 248.524.36004 Boehringer Ingelheim Investigational Site
    Sopron, Hungary
  • 248.524.36001 Boehringer Ingelheim Investigational Site
    Szeged, Hungary
  • 248.524.36006 Boehringer Ingelheim Investigational Site
    Szeged, Hungary
  • 248.524.36003 Boehringer Ingelheim Investigational Site
    Szombathely, Hungary
  • 248.524.36002 Boehringer Ingelheim Investigational Site
    Zalaegerszeg, Hungary
  • 248.524.91002 Boehringer Ingelheim Investigational Site
    Chennai, India
  • 248.524.91009 Boehringer Ingelheim Investigational Site
    Hyderabad, India
  • 248.524.91010 Boehringer Ingelheim Investigational Site
    Hyderabad, India
  • 248.524.91001 Boehringer Ingelheim Investigational Site
    Karnataka, India
  • 248.524.91005 Boehringer Ingelheim Investigational Site
    Maharashtra, India
  • 248.524.91007 Boehringer Ingelheim Investigational Site
    Maharashtra, India
  • 248.524.91004 Boehringer Ingelheim Investigational Site
    New Delhi, India
  • 248.524.91006 Boehringer Ingelheim Investigational Site
    New Delhi, India
  • 248.524.91011 Boehringer Ingelheim Investigational Site
    Pune, India
  • 248.524.81010 Boehringer Ingelheim Investigational Site
    Aomori, Aomori, Japan
  • 248.524.81001 Boehringer Ingelheim Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • 248.524.81005 Boehringer Ingelheim Investigational Site
    Fuchu, Tokyo, Japan
  • 248.524.81011 Boehringer Ingelheim Investigational Site
    Fujisawa, Kanagawa, Japan
  • 248.524.81013 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 248.524.81015 Boehringer Ingelheim Investigational Site
    Iwamizawa,Hokkaido, Japan
  • 248.524.81003 Boehringer Ingelheim Investigational Site
    Kodaira, Tokyo, Japan
  • 248.524.81014 Boehringer Ingelheim Investigational Site
    Kyoto, Kyoto, Japan
  • 248.524.81009 Boehringer Ingelheim Investigational Site
    Morioka, Iwate, Japan
  • 248.524.81008 Boehringer Ingelheim Investigational Site
    Okayama, Okayama, Japan
  • 248.524.81006 Boehringer Ingelheim Investigational Site
    Ota-ku, Tokyo, Japan
  • 248.524.81004 Boehringer Ingelheim Investigational Site
    Sagamihara, Kanagawa, Japan
  • 248.524.81007 Boehringer Ingelheim Investigational Site
    Shimogyo-ku, Kyoto, Kyoto, Japan
  • 248.524.81012 Boehringer Ingelheim Investigational Site
    Shiroishi, Miyagi, Japan
  • 248.524.81002 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
  • 248.524.60001 Boehringer Ingelheim Investigational Site
    Kuala Lumpur, Malaysia
  • 248.524.60004 Boehringer Ingelheim Investigational Site
    Kuala Terengganu, Malaysia
  • 248.524.60002 Boehringer Ingelheim Investigational Site
    Pulau Pinang, Malaysia
  • 248.524.07001 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.524.07002 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.524.07003 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.524.07004 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.524.07005 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.524.07006 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.524.42103 Boehringer Ingelheim Investigational Site
    Dubnica nad Vahom, Slovakia
  • 248.524.42101 Boehringer Ingelheim Investigational Site
    Trnava, Slovakia
  • 248.524.88603 Boehringer Ingelheim Investigational Site
    Kaohsiung, Taiwan
  • 248.524.88605 Boehringer Ingelheim Investigational Site
    Taichung, Taiwan
  • 248.524.88601 Boehringer Ingelheim Investigational Site
    Taipei, Taiwan
  • 248.524.88602 Boehringer Ingelheim Investigational Site
    Taoyuan, Taiwan
  • 248.524.38005 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 248.524.38001 Boehringer Ingelheim Investigational Site
    Lvov, Ukraine
  • 248.524.38002 Boehringer Ingelheim Investigational Site
    Uzhgorod, Ukraine
  • 248.524.38003 Boehringer Ingelheim Investigational Site
    Vinnytzya, Ukraine
  • 248.524.38004 Boehringer Ingelheim Investigational Site
    Zaporizhzhya, Ukraine
  • 248.524.38006 Boehringer Ingelheim Investigational Site
    Zaporozhye, Ukraine
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007 and a primary completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2007
First posted
May 28, 2007
Start
May 2007
Primary completionActual
Nov 2008
Results first posted
Apr 15, 2010
Last update
Jul 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00479401
Responsible party
Sponsor
First posted
May 28, 2007
Start date
May 2007
Primary completion
Nov 2008
Results posted
Apr 15, 2010
Last update
Jul 17, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion